Australia's Healius jumps on review, CEO change
March 5 (Reuters) - Healius' HLS.AX shares jumped more
than 11% on Tuesday after the healthcare firm said it would
start a review and engage investment advisers after Australia's
competition regulator killed the $1 billion takeover by rival
Australian Clinical Labs ACL.AX last year.
Healius also said Chief Financial Officer Paul Anderson will
transition to the CEO role, replacing Maxine Jaquet.
(Reporting by Ayushman Ojha; Editing by Alan Barona)
((Ayushman.Ojha@thomsonreuters.com;))
Recent news on Healius
See all newsAustralia's Healius rises on sale of unit Agilex; Jefferies lifts PT
Brief: Healius To Sell Agilex Biolabs To Novotech
Australia's Healius rises on sale of unit Agilex Biolabs to Novotech Health
Brief: Healius Requests Trading Halt
Brief: Healius Expects To Achieve T27 Target Of Mid-To-High Single-Digit EBIT Margins By Dec 2028